The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone

Medical Hypotheses

Volumn 84, Issue 1, 2015, Pages 78-80

  Puri, B K ^a   Hakkarainen Smith, J S ^b   Monro, Jean A ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Breakspear Medical Group Hemel Hempstead   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; COLESTYRAMINE; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INCIDENCE; LYME DISEASE; MALE; BIOLOGICAL MODEL; COHORT ANALYSIS; METABOLISM; MICROBIOLOGY; PILOT STUDY;

CLOSTRIDIUM DIFFICILE;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CEFTRIAXONE; CHOLESTYRAMINE RESIN; COHORT STUDIES; DIARRHEA; ENTEROTOXINS; HUMANS; LYME DISEASE; MODELS, BIOLOGICAL; PILOT PROJECTS;

EID: 84918575278     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.11.020     Document Type: Article

References (18)

1. Wu C.K., Wang J.H., Lee C.H., Wu K.L., Tai W.C., Lu S.N., et al. The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage. PLoS One 2013, 8:e61666.
2. Kaiser R. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 2004, 75:553-557.
3. Rohacova H., Hancil J., Hulinska D., Mailer H., Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. Infection 1996, 24:88-90.
4. Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease-New Jersey, 1990-1992. JAMA 1993, 269:979-980. CDC.
5. Pfister H.W., Preac-Mursic V., Wilske B., Schielke E., Sorgel F., Einhaupl K.M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991, 163:311-318.
6. Feurle G.E., Moos V., Blaker H., Loddenkemper C., Moter A., Stroux A., et al. Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim-sulfamethoxazole in Whipple's disease. J Infect 2013, 66:263-270.
7. Cadavid D. Spirochetal infections. Handb Clin Neurol 2010, 96:179-219.
8. Privitera G., Scarpellini P., Ortisi G., Nicastro G., Nicolin R., de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991, 35:208-210.
9. Westh H., Iversen J.T., Gyrtrup H.J. Clostridium difficile in faecal flora after perioperative prophylaxis with ampicillin or ceftriaxone. J Infect 1991, 23:347-350.
10. Scaldaferri F., Pizzoferrato M., Ponziani F.R., Gasbarrini G., Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med 2013, 8:205-210.
11. Sebastian-Ochoa A., Quesada-Charneco M., Fernandez-Garcia D., Reyes-Garcia R., Rozas-Moreno P., Escobar-Jimenez F. Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy. Thyroid 2008, 18:1115-1117.
12. Kaykhaei M.A., Shams M., Sadegholvad A., Dabbaghmanesh M.H., Omrani G.R. Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine 2008, 34:52-55.
13. Flieger D., Klassert C., Hainke S., Keller R., Kleinschmidt R., Fischbach W. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 2007, 72:10-16.
14. Palace G.P., Lazari P., Norton K. Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. Biochim Biophys Acta 2001, 1546:171-184.
15. Olling A., Huls C., Goy S., Muller M., Krooss S., Rudolf I., et al. The combined repetitive oligopeptides of Clostridium difficile toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation. Toxins (Basel) 2014, 6:2162-2176.
16. Baliban S.M., Michael A., Shammassian B., Mudakha S., Khan A.S., Cocklin S., et al. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun 2014, 82:4080-4091.
17. British national formulary 2014, Joint Formulary Committee, BMJ Group and Pharmaceutical Press, London. 68 ed.
18. Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman & Gilman's the pharmacological basis of therapeutics 2011, 877-908. McGraw-Hill, New York. 12th ed. L.L. Brunton, B. Chabner, B.C. Knollmann (Eds.).